Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia
- PMID:34426949
- DOI: 10.1007/s40263-021-00854-5
Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia
Abstract
Despite significant progress in the understanding of the frontotemporal dementias (FTDs), there remains no disease-modifying treatment for these conditions, and limited effective symptomatic treatment. Behavioural variant frontotemporal dementia (bvFTD) is the most common FTD syndrome, and is characterized by severe impairments in behaviour, personality and cognition. Neuropsychiatric symptoms are common features of bvFTD but are present in the other FTD syndromes. Current treatment strategies therefore focus on ameliorating the neuropsychiatric features. Here we review the rationale for current treatments related to each of the main neuropsychiatric symptoms forming the diagnostic criteria for bvFTD relevant to all FTD subtypes, and two additional symptoms not currently part of the diagnostic criteria: lack of insight and psychosis. Given the paucity of effective treatments for these symptoms, we highlight how contributing mechanisms delineated in cognitive neuroscience may inform future approaches to clinical trials and more precise symptomatic treatments for FTDs.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
- Behavioural and neuropsychiatric disturbance in three clinical subtypes of frontotemporal dementia: A Clinical Research Center for Dementia of South Korea-FTD Study.Park MH, Kim EJ, Park KW, Kwon JC, Ku BD, Han SH, Kim S, Yang DW, Na DL, Choi SH.Park MH, et al.Australas J Ageing. 2017 Mar;36(1):46-51. doi: 10.1111/ajag.12374.Australas J Ageing. 2017.PMID:28326689
- The Frontotemporal Dementia versus Primary Psychiatric Disorder (FTD versus PPD) Checklist: A Bedside Clinical Tool to Identify Behavioral Variant FTD in Patients with Late-Onset Behavioral Changes.Ducharme S, Pearl-Dowler L, Gossink F, McCarthy J, Lai J, Dickerson BC, Chertkow H, Rapin L, Vijverberg E, Krudop W, Dols A, Pijnenburg Y.Ducharme S, et al.J Alzheimers Dis. 2019;67(1):113-124. doi: 10.3233/JAD-180839.J Alzheimers Dis. 2019.PMID:30584146
- Defining Neuropsychiatric Inventory scale differences across frontotemporal dementia syndromes.Yiannopoulou KG, Papatriantafyllou JD, Ghika A, Tsinia N, Lykou E, Hatziantoniou E, Agiomyrgiannakis D, Kyrozis A, Papageorgiou SG.Yiannopoulou KG, et al.Psychogeriatrics. 2019 Jan;19(1):32-37. doi: 10.1111/psyg.12358. Epub 2018 Aug 2.Psychogeriatrics. 2019.PMID:30073726
- Therapy and clinical trials in frontotemporal dementia: past, present, and future.Tsai RM, Boxer AL.Tsai RM, et al.J Neurochem. 2016 Aug;138 Suppl 1(Suppl 1):211-21. doi: 10.1111/jnc.13640. Epub 2016 Jun 15.J Neurochem. 2016.PMID:27306957Free PMC article.Review.
- Frontotemporal dementia.Miller B, Llibre Guerra JJ.Miller B, et al.Handb Clin Neurol. 2019;165:33-45. doi: 10.1016/B978-0-444-64012-3.00003-4.Handb Clin Neurol. 2019.PMID:31727221Review.
Cited by
- Mental health care for older adults: recent advances and new directions in clinical practice and research.Reynolds CF 3rd, Jeste DV, Sachdev PS, Blazer DG.Reynolds CF 3rd, et al.World Psychiatry. 2022 Oct;21(3):336-363. doi: 10.1002/wps.20996.World Psychiatry. 2022.PMID:36073714Free PMC article.
- Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice.Santos-García I, Rodríguez-Cueto C, Villegas P, Piscitelli F, Lauritano A, Shen CJ, Di Marzo V, Fernández-Ruiz J, de Lago E.Santos-García I, et al.J Neuroinflammation. 2023 May 6;20(1):108. doi: 10.1186/s12974-023-02792-z.J Neuroinflammation. 2023.PMID:37149645Free PMC article.
- Sodium selenate as a therapeutic for tauopathies: A hypothesis paper.Dilcher R, Malpas CB, Walterfang M, Velakoulis D, O'Brien TJ, Vivash L.Dilcher R, et al.Front Aging Neurosci. 2022 Aug 5;14:915460. doi: 10.3389/fnagi.2022.915460. eCollection 2022.Front Aging Neurosci. 2022.PMID:35992608Free PMC article.
- Occupational Therapy Interventions in Patients with Frontotemporal Dementia: A Systematic Review.Vlotinou P, Tsiakiri A, Detsaridou G, Nikova A, Tsiptsios D, Vadikolias K, Aggelousis N.Vlotinou P, et al.Med Sci (Basel). 2023 Nov 6;11(4):71. doi: 10.3390/medsci11040071.Med Sci (Basel). 2023.PMID:37987326Free PMC article.Review.
- Distinct and shared neuropsychiatric phenotypes in FTLD-tauopathies.Keszycki R, Kawles A, Minogue G, Zouridakis A, Macomber A, Gill N, Vu M, Zhang H, Coventry C, Rogalski E, Weintraub S, Mesulam MM, Geula C, Gefen T.Keszycki R, et al.Front Aging Neurosci. 2023 Jun 9;15:1164581. doi: 10.3389/fnagi.2023.1164581. eCollection 2023.Front Aging Neurosci. 2023.PMID:37358954Free PMC article.
References
- Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet Lond Engl. 2015;386:1672–82. - DOI
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources